According to a study led by researchers at UCLA, the Alzheimer’s drug Leqembi would raise future costs for Medicare by $2 billion to $5 billion a year. Leqembi, sold for …
Study finds Alzheimer’s drug Leqembi would cost Medicare up to $5 billion a year Read More »
A late-stage clinical trial was conducted by Biogen and Eisai and the new Alzheimer’s drug they are developing for Alzheimer’s disease slowed the rate of cognitive decline. New Alzheimer’s Drug …
Research Study Shows New Alzheimer’s Drug Slows Cognitive Decline Read More »
Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly …
First Florida Patient to Receive Biogen Aducanumab Infusion Read More »
In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause …
Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the …
Do you suffer from post-COVID-19 syndrome, also referred to as COVID-19 Long-Haulers? Symptoms may include fatigue, shortness of breath, headaches, dizziness, trouble sleeping, and brain fog, or difficulty thinking clearly. …
